12:00pm PT/3:00pm ET
CME Credit Hours: 1.0
Assessment of Comorbidities for Hematopoietic Cell Transplants: Achievements and Controversies
Mahmoud Elsawy, MD, MSc (Dalhousie University, Halifax, NS)
Dr. Elsawy is an Assistant Professor of Hematology, Dalhousie University, Canada and Affiliate Investigator at Fred Hutch, Seattle. He graduated from Cairo University School of Medicine, Egypt in 2007. He finished his Medicine and Hematology/Oncology training at the National Cancer Institute of Egypt. Following this, he was awarded a scholarship to join Fred Hutch/ University of Washington, Seattle between 2013 and 2016 for a postdoctoral fellowship in Stem cell Transplantation under the mentorship of Dr. Mohamed Sorror. His research focus was around the impact of comorbidities on outcomes of transplant recipients, treatment of AML in the elderly population, and survivorship following BMT. He then joined the Leukemia and Bone Marrow Transplant Program in Vancouver, BC where he completed a clinical fellowship between 2016 and 2018. He joined the BMT Program at Dalhousie University as an Assistant Professor of Hematology and Stem Cell Transplantation in 2018 where he currently focuses on optimization of pre-transplant comorbidities to improve post-transplantation outcomes in the elderly population and on long term follow up and management of chronic graft versus host disease where he established a LTFU clinic for transplant survivors. Additionally, he has special interests in management of myeloid malignancies in older adults and in providing CAR T-cell therapy. Dr. Elsawy is the Lead for establishing a future regional CAR T-cell Therapy Program in Halifax.
Allogeneic conventional HCT (hematopoietic cell transplantation) is a potentially curative therapy for many patients with hematologic malignant or nonmalignant diseases. Historically, conditioning regimens for conventional HCT have been intensified to the limits of organ tolerance in order to optimize cancer eradication. Consequently, serious toxicities to organs, such as gut, lung, kidney, heart, and liver, have been observed which, additionally, have limited the ability to deliver adequate doses of postgrafting immunosuppression needed for control of graft-versus-host disease (GvHD). The use of reduced intensity regimens has expanded the use of HCT to include elderly and comorbid patients with various hematologic malignancies. Therefore, it has become important to comprehensive study differences in comorbidities among patient groups, to investigate the impacts of comorbidities on HCT outcomes and quality of life, and to standardize comorbidity assessment for future clinical trials.
1. Describing the milestones of evolution of comorbidities research in HCT
2. Highlighting the relevance of comprehensive comorbidities assessment
3. Reviewing the utilization of Hematopoietic cell transplantation specific- comorbidity index (HCT-CI)
4. Assessing strengths and weaknesses of the HCT-CI with a focus on methodology for calculating the HCT-CI score
5. Thoughts for the future
This webinar is sponsored by an unrestricted education grant from
*NEW* We have updated our webinar registration process. After completing your registration on our website you will be asked to finalize your registration with GoToWebinar to receive a confirmation email containing all of the information about joining the webinar.